Status:
COMPLETED
Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate with Ultimate Dosing
Lead Sponsor:
Walton Centre NHS Foundation Trust
Collaborating Sponsors:
Instituto Grifols, S.A.
Conditions:
Multifocal Motor Neuropathy (MMN)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Eligibility:
All Genders
18+ years
Brief Summary
CIDP and MMN are part of a group of chronic inflammatory conditions that affect the peripheral nervous system. In CIDP, there is chronic inflammation of the peripheral nerves and nerve roots leading t...
Detailed Description
The study is designed to slot into normal clinical care, with some extra blood tests performed at times patients would already be attending hospital. An extra blood test is desired 1 week following in...
Eligibility Criteria
Inclusion
- Adult patients with CIDP or MMN who are starting Intravenous immunoglobulin in the Walton Centre
- Informed consent
Exclusion
- Previous Intravenous immunoglobulin use in the last year
- Age under 18
- Lack of mental capacity to consent to treatment or to study participation
- Concurrent treatment with steroids or other immunosuppressants
Key Trial Info
Start Date :
September 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04356781
Start Date
September 28 2020
End Date
December 30 2024
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Walton Centre NHS Foundation Trust
Liverpool, Merseyside, United Kingdom, L9 7LJ